October 2009 PMID 19847319

Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial.

David C Crowley, Francis C Lau, Prachi Sharma, Malkanthi Evans, Najla Guthrie, Manashi Bagchi, Debasis Bagchi, Dipak K Dey, Siba P Raychaudhuri

Download social card

Mentions

Peak: 1 in Jan 2022

across 4 sources since Jan 2022

Extended reach

228,704

potential audience

Total likes

7,786

Video views

228,458

Mentions per month

Jan 2022 – May 2025

Where it's discussed

News38 articles
Facebook6 posts
YouTube4 videos
X / Twitter1 posts

AI synopsis

What people are saying

Many discussions highlight the promising findings, such as mentions of reduced pain and improved joint function, with phrases like 'significant improvement' and 'more effective than glucosamine'. The tone indicates a positive perception of UCII's potential benefits, but the depth of engagement remains limited and primarily focused on individual outcomes.

AgreementModerate agreement

Most discussions acknowledge the positive results of the clinical trial, with some explicit support for UCII's effectiveness over traditional supplements.

InterestModerate interest

Participants show moderate curiosity about the study, often referencing the significant improvements without delving deeply into mechanisms or broader implications.

EngagementNeutral engagement

The conversations are somewhat surface-level, with brief mentions of specific score improvements, but little detailed debate or analysis.

ImpactModerate impact

These discussions suggest the research could influence perceptions of osteoarthritis treatments, but they do not demonstrate widespread or transformative influence yet.

Abstract in brief

The clinical trial found that undenatured type II collagen (UCII) is safer and more effective than a combination of glucosamine and chondroitin (GC) in treating knee osteoarthritis, showing significant improvements in pain and function after 90 days.
UCII treatment reduced osteoarthritis symptoms more than GC, with greater declines in WOMAC and VAS scores, indicating less pain and better joint function.
Patients taking UCII experienced notable improvements in daily activities and quality of life, as evidenced by the greater reduction in Lequesnes functional index scores compared to the GC group.]

Read the full abstract